Quick Answer
RetinalGenix Technologies Inc. reported Net Income of -$4.32 million for fiscal year 2024.
RetinalGenix Technologies Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$4.32M -106.7% |
-$2.09M +46.6% |
-$3.91M -79.6% |
-$2.18M -4.9% |
-$2.08M | — |
| Diluted EPS | -$0.24 -100.0% |
-$0.12 +52.0% |
-$0.25 | — | — | — |
| Total Assets | $14.9K +9480.8% |
$156.00 -46.9% |
$294.00 -94.1% |
$4.9K -91.9% |
$61.1K | — |
| Cash and Equivalents | — | — | $38.00 -99.2% |
$4.9K +122.9% |
$2.2K | — |
| Stockholders Equity | -$1.46M -4.1% |
-$1.41M -31.5% |
-$1.07M -130.1% |
-$464.7K -478.3% |
-$80.4K -432.5% |
$24.2K |
| R&D Expense | $373.3K -28.8% |
$524.2K | — | $680.3K +57.6% |
$431.6K | — |
| Shares Outstanding | 18.52M +5.0% |
17.64M +2.1% |
17.27M +21.4% |
14.22M -65.0% |
40.68M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$568.8K | +11.7% | +12.4% |
| Diluted EPS | September 30, 2025 | -$0.03 | +25.0% | +11.8% |
| Total Assets | September 30, 2025 | $7.0K | -92.1% | -16.5% |
| Cash and Equivalents | September 30, 2023 | $44.00 | -98.8% | -97.7% |
| Stockholders Equity | September 30, 2025 | -$2.17M | -17.2% | -9.7% |
| R&D Expense | September 30, 2025 | $20.5K | -80.1% | +41.7% |
| Shares Outstanding | September 30, 2025 | 18.60M | +3.0% | +0.2% |
- RetinalGenix Technologies Inc. reported Net Income of -$4.32 million for fiscal year 2024.
- RetinalGenix Technologies Inc. showed a decrease of -106.7% in Net Income compared to the prior fiscal year.
- RetinalGenix Technologies Inc. reported Diluted EPS of $0.24 per share (loss) for fiscal year 2024.
- RetinalGenix Technologies Inc. showed a decrease of -100.0% in Diluted EPS compared to the prior fiscal year.
- RetinalGenix Technologies Inc. reported Total Assets of $14.9 thousand for fiscal year 2024.
- RetinalGenix Technologies Inc. showed an increase of +9480.8% in Total Assets compared to the prior fiscal year.
- RetinalGenix Technologies Inc. reported Cash and Equivalents of $38.00 for fiscal year 2022.
- RetinalGenix Technologies Inc. showed a decrease of -99.2% in Cash and Equivalents compared to the prior fiscal year.
- RetinalGenix Technologies Inc. reported Stockholders Equity of -$1.46 million for fiscal year 2024.
- RetinalGenix Technologies Inc. showed a decrease of -4.1% in Stockholders Equity compared to the prior fiscal year.
- RetinalGenix Technologies Inc. reported R&D Expense of $373.3 thousand for fiscal year 2024.
- RetinalGenix Technologies Inc. showed a decrease of -28.8% in R&D Expense compared to the prior fiscal year.
- RetinalGenix Technologies Inc. reported Shares Outstanding of 18.52 million shares for fiscal year 2024.
- RetinalGenix Technologies Inc. showed an increase of +5.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: